Document |
Document Title |
WO/2001/051506A2 |
The invention relates to nonpeptide oligomers of amino acids. The oligomers comprise -(NR'-A-CO)-O- units which represent a nonpeptide, restricted-mimetic inducer of the $g(b) turn in a dipeptide or tripeptide fragment. Said oligomers ma...
|
WO/2001/032639A1 |
The invention is directed to nonpeptide substituted benzodiazepines of Formula (I), wherein A, X, Z, Bp, W, n, R?1¿ and R?2¿ are as described in the specification, which are useful as vasopressin receptor antagonists for treating condi...
|
WO/2001/004106A1 |
A process for producing dibenzothiazepine derivatives typified by dibenzo[b,f][1,4]thiazepin-11-one which are usable as the starting material for producing 11-[4-(2-(2-hydroxyethoxy)ethyl)]-1-piperazinyldibenzothiaze
pine derivatives use...
|
WO/2001/000185A2 |
The present invention provides a method of treating obesity and related conditions such as bulimia, anorexia, snacking, binge eating, non insolin dependent diabetes meltitus, hyperglycaemia, stress, hyperlipidaemia, and to aid to smoking...
|
WO/2000/071106A2 |
A method of treating weight in patients, in particular those suffering from psychoses, by administering the antipsychotic agent quetiapine.
|
WO/2000/061568A2 |
The invention relates to substituted 1,4-benzothiazepine-1,1-dioxide derivatives and to the acid addition salts thereof. The invention discloses 1,4-benzothiazepine-1,1-dioxide derivatives of formula (I), wherein R?1¿, R?2¿, R?3¿ and ...
|
WO/2000/058294A1 |
Compounds of formula (I) are antibacterial agents wherein: R¿3? and R¿4?, taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 1...
|
WO/2000/047568A2 |
Novel 1,1-dioxido-1,2-benzothiazepines, derivatives and analogs thereof, pharmaceutical compositions containing them, and their use in medicine, particularly in the prophylaxis and/or treatment of hyperlipidemic diseases, conditions and/...
|
WO/2000/044709A2 |
Compound of the formula (B) are useful in treating disease conditions mediated by TNF-$g(a), such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage l...
|
WO/2000/042031A2 |
This invention relates to 2-arylimino heterocycles, including 2-arylimino-1, 3-thiazolidines, 2-arylimino-2, 3, 4, 5-tetrahydro-1, 3-thiazines, 2-arylimino-1, 3-thiazolidin-4-ones, 2-arylimino-1, 3-thiazolidin-5-ones, and 2-arylimino-1, ...
|
WO/2000/038728A1 |
The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed inc...
|
WO/2000/023416A1 |
The present invention relates to compounds of general formula (Ia). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (P...
|
WO/2000/020006A1 |
The invention concerns the use of a calcium channel blocker compound and/or cyclic GMP-dependent channels, namely diltiazem, for treating retinal pathologies, and more particularly retinal diseases caused by degeneration of visual recept...
|
WO/2000/017384A1 |
A process for the preparation of formula (I) in which R and R1 have the meanings reported in the description, that comprises the enzymatic kinetic resolution by transesterification with aminoalcohols of 3-phenylglycidates of formula (I),...
|
WO/2000/005246A1 |
The invention concerns a thioazepinone derivative of formula (I) wherein: R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, X, [A¿1?], A¿2? and U have the meanings given in the description, their salts and their pro-drugs. The invention further conce...
|
WO/1999/067219A1 |
Compounds of formula (I), wherein $i(W) is a cyclic group of the type (2); (3); $i(Y) is represented by the formula (II); these compounds inhibit $g(b)-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treat...
|
WO/1999/067230A1 |
The present invention relates to compound of formula (I), that are potent inhibitors of $g(a)¿4?$g(b)¿1? mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the m...
|
WO/1999/066934A1 |
Disclosed are compounds which inhibit $g(b)-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits...
|
WO/1999/058531A1 |
The present application describes novel substituted aryl hydroxamic acids of formula (I) or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-1 additional heteroatoms selected from N,...
|
WO/1999/035135A1 |
The invention is concerned with novel hypolipidemic compounds of formula (I), wherein R?1¿ is H or methyl, and salts, solvates or physiologically functional derivatives thereof, with processes and novel intermediates for their preparati...
|
WO/1999/022014A1 |
A novel process for preparing a (2R,3S)-3-(4-lower alkoxyphenyl)glycidic acid ester and a process for preparing a (2S,3S)-1,5-benzothiazepine compound, which is useful as a medicine, using the same are provided; and the (2R,3S)-3-(4-lowe...
|
WO/1999/020603A1 |
A process which allows the re-use of compounds of formula (III-(2R, 3R)) in diltiazem synthesis through a process of conversion to a mixture of enantiomers III-(2R,3R) and III-(2S,3S) is described.
|
WO1998038182A9 |
The invention concerns compounds of formula (I) wherein: I is an integer of from 1 to 4; m is an integer of from 0 to 2; R is independently selected from hydrogen, halogen, nitro, hydroxy, phenylalkoxy, C1-4 alkoxy, C1-6 alkyl, -SO3R'', ...
|
WO/1999/009991A1 |
Disclosed are the novel compounds represented by structural Formula (I), wherein A is a lipophilic group comprising an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group a...
|
WO/1999/007875A1 |
A novel process for preparing (2R,3S)-3-(substituted or unsubstituted phenyl)glycidamide compounds, characterized by reacting a racemic trans-3-(substituted or unsubstituted phenyl)glycidic ester compound with ammonia or an amine compoun...
|
WO/1999/006049A1 |
Compounds of the formula (I) are disclosed which are dual fibrinogen receptor and vitronectin receptor antagonists and are useful in the treatment of atherosclerosis, in the prevention of restenosis and in the prevention of tumor metasta...
|
WO/1999/006381A1 |
Crystalline 11-(4-[2-(2-hydroxyethoxy) ethyl]-1-piperazinyl)-dibenzo[b,f] [1,4]thiazepine (I) may be prepared by crystallising 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b,f]
[1,4]thiazepine from a non-aromatic solvent such ...
|
WO/1999/005147A1 |
The invention concerns compounds of formula (I) in which: R¿1? represents a sulphur or selenium atom; R¿2? represents a hydrogen atom or an alkyl radical; -R¿3?-R¿4?-R¿5?-R¿6?- represents a chain of formula -CH¿2?-CH¿2?-CH¿2?-CH...
|
WO/1998/056762A2 |
A process for preparing an optically active phenyloxirane compound represented by formula (II), wherein ring A is a substitued or unsubstituted benzene ring; R is a group represented by -CO�2?R?q�, or a group convertible to the group...
|
WO/1998/047882A1 |
The present invention provides a compound of formula (I), wherein ring A is an optionally substituted aromatic hydrocarbon ring or aromatic heterocyclic ring; ring B is an optionally substituted aromatic hydrocarbon ring or aromatic hete...
|
WO/1998/041510A1 |
Compounds represented by general formula (I), pharmaceutically acceptable salts thereof, or hydrates of these; pharmaceutical compositions comprising the same; a method for inhibiting feeding characterized by administering the same; a me...
|
WO/1998/035941A1 |
Compounds represented by general formula (I) or pharmacologically acceptable salts thereof, or hydrates of both, (wherein R?1� and R?2� are each independently a hydrogen atom, a halogen atom, etc.; R?3� is a lower alkyl group which...
|
WO/1998/035939A1 |
Malonic diamide derivatives represented by general formula (I) and nontoxic salts thereof, having a cholesterol acyl transferase inhibitory activity, wherein R1, R2, and R3 represent each a hydrogen atom, a halogen atom, a lower alkyl gr...
|
WO/1998/028268A2 |
Disclosed are compounds for Formula (I) wherein the substituents are as defined in the claims which inhibit $g(b)-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclose...
|
WO/1998/015278A1 |
A method for stimulating bone formation by administering integrin binding compounds which cause the release of osteocalcin from osteoblasts is disclosed.
|
WO/1998/014433A1 |
Compounds of the formula (I) wherein R?1� is a group of formula G?1�, G?2�, G?3�, G?4�, G?5�, G?6� or G?7�; Y is an optionally substituted (C�1?-C�4?) heteroalkyl bridge that, together with the atoms to which it is at...
|
WO/1998/008505A1 |
The invention provides novel cryptophycin compounds which can be useful for disrupting the microtubulin system, as anti-neoplastic agents, and for the treatment of cancer. The invention further provides a formulation for administering th...
|
WO/1998/008823A1 |
The invention provides compounds of formula (I) as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as ...
|
WO/1998/008825A1 |
The invention provides compounds of formula (I) as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as ...
|
WO/1998/008827A1 |
The invention provides compounds of formula (I) as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful inh...
|
WO/1998/005657A1 |
The application concerns compounds (I) wherein R�1?, R�2?, R�3? and R�4? are H, halo, (halo)alkyl or (halo)alkoxy, which are prepared from compounds (II) or (III), or directly from compounds (IV) and (V): H�2?N(CH�2?)�2?SH ...
|
WO/1998/001417A1 |
Novel calcium receptor-active compounds represented by the following general formula: Ar�1?-[CR?1�R?2�]�p?-X-[CR?3�R?4�]�q?-[CR?5�
R?6�]-NR?7�-[CR?8�R?9�]-Ar�2? wherein Ar�1? is selected from the group consist...
|
WO/1998/001164A1 |
Herein described are radiolabeled compounds useful to image D4 receptors $i(in vivo), of formula (I), wherein X?1� is selected from NH, O and S; X?2� is selected from CH and N; Z is selected from iodide, cyano, nitro, tri(loweralkyl)...
|
WO/1997/048396A1 |
A method for the treatment of liver disease selected from the group consisting of cirrhosis of the liver, toxic and medicamentary liver damage, a liver parenchymic disorder or hepatitis, which method includes administering to a human or ...
|
WO/1997/047625A1 |
Tricyclic compounds of general formula (I) as defined herein which exhibit antagonist activity at V1 and/or V2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases character...
|
WO/1997/030054A1 |
The present invention relates to pharmaceutically acceptable compounds, including certain substituted indolinyl and derivatives thereof, 1,2,3,4-tetrahydroquinolinyl and derivatives thereof, 1,2,3,4-tetrahydroisoquinolinyl, benz[cd]indol...
|
WO/1997/023219A1 |
Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof...
|
WO/1997/021685A1 |
A compound of formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
|
WO/1997/017344A1 |
There are provided novel compounds of formula (I), wherein X, R1, R2, R3, R4 and R5 are as defined in the specification and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for ...
|
WO/1997/016430A1 |
Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, di...
|